VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Reviewing Key Genomic Assays in Breast Cancer

Discussant: David J. Dabbs, MD, Pittsburgh
Published: Thursday, Apr 02, 2015
For High-Definition, Click
A number of assays are available for testing breast cancer tissue, including Oncotype DX, MammaPrint, and Prosigna, David J. Dabbs, MD, states. Each of these tests has undergone various validation methodologies and can be conducted using formalin-fixed paraffin embedded (FFPE) blocks. To date, both the Prosigna and the Mammaprint tests are FDA approved for use with FFPE biopsies.

Prosigna is designed as a prognostic indicator of distant recurrence-free survival in postmenopausal women with HR-positive stage I/II breast cancer. Oncotype DX is intended for newly diagnosed patients with ER-positive, HER2-negative invasive breast cancer. The MammaPrint test can be utilized for most patients with early-stage breast cancer, regardless of HR and HER2 status.

Each of these tests are classified as in vitro diagnostic multivariate index assays (IVDMIA), defined as a combination of multiple variables that are interpreted using an algorithmic function. These tests are complex, with results that are difficult to translate for patients, requiring proper administration by pathologists, Dabbs notes. These assays are subject to FDA regulation, which helps to ensure accuracy. 

Many of these molecular tests provide online ordering systems, local laboratory options, and the ability to review test results online. These tests can be ordered relatively simply, Dabbs suggests. 

Slider Left
Slider Right
For High-Definition, Click
A number of assays are available for testing breast cancer tissue, including Oncotype DX, MammaPrint, and Prosigna, David J. Dabbs, MD, states. Each of these tests has undergone various validation methodologies and can be conducted using formalin-fixed paraffin embedded (FFPE) blocks. To date, both the Prosigna and the Mammaprint tests are FDA approved for use with FFPE biopsies.

Prosigna is designed as a prognostic indicator of distant recurrence-free survival in postmenopausal women with HR-positive stage I/II breast cancer. Oncotype DX is intended for newly diagnosed patients with ER-positive, HER2-negative invasive breast cancer. The MammaPrint test can be utilized for most patients with early-stage breast cancer, regardless of HR and HER2 status.

Each of these tests are classified as in vitro diagnostic multivariate index assays (IVDMIA), defined as a combination of multiple variables that are interpreted using an algorithmic function. These tests are complex, with results that are difficult to translate for patients, requiring proper administration by pathologists, Dabbs notes. These assays are subject to FDA regulation, which helps to ensure accuracy. 

Many of these molecular tests provide online ordering systems, local laboratory options, and the ability to review test results online. These tests can be ordered relatively simply, Dabbs suggests. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x